583 related articles for article (PubMed ID: 24950360)
1. Evaluation of single-round infectious, chimeric dengue type 1 virus as an antigen for dengue functional antibody assays.
Yamanaka A; Suzuki R; Konishi E
Vaccine; 2014 Jul; 32(34):4289-95. PubMed ID: 24950360
[TBL] [Abstract][Full Text] [Related]
2. High-throughput neutralization assay for multiple flaviviruses based on single-round infectious particles using dengue virus type 1 reporter replicon.
Matsuda M; Yamanaka A; Yato K; Yoshii K; Watashi K; Aizaki H; Konishi E; Takasaki T; Kato T; Muramatsu M; Wakita T; Suzuki R
Sci Rep; 2018 Nov; 8(1):16624. PubMed ID: 30413742
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of chimeric DNA vaccines consisting of premembrane and envelope genes of Japanese encephalitis and dengue viruses as a strategy for reducing induction of dengue virus infection-enhancing antibody response.
Sjatha F; Kuwahara M; Sudiro TM; Kameoka M; Konishi E
Microbiol Immunol; 2014 Feb; 58(2):126-34. PubMed ID: 24372832
[TBL] [Abstract][Full Text] [Related]
4. Seroprevalence of Flavivirus Neutralizing Antibodies in Thailand by High-Throughput Neutralization Assay: Endemic Circulation of Zika Virus before 2012.
Yamanaka A; Matsuda M; Okabayashi T; Pitaksajjakul P; Ramasoota P; Saito K; Fukasawa M; Hanada K; Matsuura T; Muramatsu M; Shioda T; Suzuki R
mSphere; 2021 Aug; 6(4):e0033921. PubMed ID: 34259560
[TBL] [Abstract][Full Text] [Related]
5. Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection.
Sasaki T; Setthapramote C; Kurosu T; Nishimura M; Asai A; Omokoko MD; Pipattanaboon C; Pitaksajjakul P; Limkittikul K; Subchareon A; Chaichana P; Okabayashi T; Hirai I; Leaungwutiwong P; Misaki R; Fujiyama K; Ono K; Okuno Y; Ramasoota P; Ikuta K
Antiviral Res; 2013 Jun; 98(3):423-31. PubMed ID: 23545366
[TBL] [Abstract][Full Text] [Related]
6. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
[TBL] [Abstract][Full Text] [Related]
7. Pseudo-infectious reporter virus particles for measuring antibody-mediated neutralization and enhancement of dengue virus infection.
Mukherjee S; Pierson TC; Dowd KA
Methods Mol Biol; 2014; 1138():75-97. PubMed ID: 24696332
[TBL] [Abstract][Full Text] [Related]
8. Complement-independent dengue virus type 1 infection-enhancing antibody reduces complement-dependent and -independent neutralizing antibody activity.
Yamanaka A; Konishi E
Vaccine; 2016 Dec; 34(51):6449-6457. PubMed ID: 27866774
[TBL] [Abstract][Full Text] [Related]
9. Utility of Japanese encephalitis virus subgenomic replicon-based single-round infectious particles as antigens in neutralization tests for Zika virus and three other flaviviruses.
Yamanaka A; Moi ML; Takasaki T; Kurane I; Matsuda M; Suzuki R; Konishi E
J Virol Methods; 2017 May; 243():164-171. PubMed ID: 28219763
[TBL] [Abstract][Full Text] [Related]
10. Development and characterization of serotype-specific monoclonal antibodies against the dengue virus-4 (DENV-4) non-structural protein (NS1).
Gelanew T; Hunsperger E
Virol J; 2018 Feb; 15(1):30. PubMed ID: 29409531
[TBL] [Abstract][Full Text] [Related]
11. Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E protein.
Budigi Y; Ong EZ; Robinson LN; Ong LC; Rowley KJ; Winnett A; Tan HC; Hobbie S; Shriver Z; Babcock GJ; Alonso S; Ooi EE
PLoS Negl Trop Dis; 2018 Feb; 12(2):e0006209. PubMed ID: 29425203
[TBL] [Abstract][Full Text] [Related]
12. Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy.
Flingai S; Plummer EM; Patel A; Shresta S; Mendoza JM; Broderick KE; Sardesai NY; Muthumani K; Weiner DB
Sci Rep; 2015 Jul; 5():12616. PubMed ID: 26220099
[TBL] [Abstract][Full Text] [Related]
13. Japanese encephalitis vaccine-facilitated dengue virus infection-enhancement antibody in adults.
Saito Y; Moi ML; Takeshita N; Lim CK; Shiba H; Hosono K; Saijo M; Kurane I; Takasaki T
BMC Infect Dis; 2016 Oct; 16(1):578. PubMed ID: 27756212
[TBL] [Abstract][Full Text] [Related]
14. Mechanism and significance of cell type-dependent neutralization of flaviviruses.
Mukherjee S; Dowd KA; Manhart CJ; Ledgerwood JE; Durbin AP; Whitehead SS; Pierson TC
J Virol; 2014 Jul; 88(13):7210-20. PubMed ID: 24741083
[TBL] [Abstract][Full Text] [Related]
15. [Investigation of dengue virus and yellow fever virus seropositivities in blood donors from Central/Northern Anatolia, Turkey].
Ergünay K; Saygan MB; Aydoğan S; Litzba N; Niedrig M; Pınar A; Us D
Mikrobiyol Bul; 2010 Jul; 44(3):415-24. PubMed ID: 21063991
[TBL] [Abstract][Full Text] [Related]
16. Universal Dengue Vaccine Elicits Neutralizing Antibodies against Strains from All Four Dengue Virus Serotypes.
Uno N; Ross TM
J Virol; 2021 Jan; 95(4):. PubMed ID: 33208445
[TBL] [Abstract][Full Text] [Related]
17. Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope.
Metz SW; Thomas A; White L; Stoops M; Corten M; Hannemann H; de Silva AM
Virol J; 2018 Apr; 15(1):60. PubMed ID: 29609659
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies that bind to common epitopes on the dengue virus type 2 nonstructural-1 and envelope glycoproteins display weak neutralizing activity and differentiated responses to virulent strains: implications for pathogenesis and vaccines.
Falconar AK
Clin Vaccine Immunol; 2008 Mar; 15(3):549-61. PubMed ID: 18160621
[TBL] [Abstract][Full Text] [Related]
19. Generation and characterization of a monoclonal antibody that cross-reacts with the envelope protein from the four dengue virus serotypes.
León-Juárez M; García-Cordero J; Santos-Argumedo L; Romero-Ramírez H; García-Machorro J; Bustos-Arriaga J; Gutiérrez-Castañeda B; Sepúlveda NV; Mellado-Sánchez G; Cedillo-Barrón L
APMIS; 2013 Sep; 121(9):848-58. PubMed ID: 23331315
[TBL] [Abstract][Full Text] [Related]
20. Expression of enhancing-activity-free neutralizing antibody against dengue type 1 virus in plasmid-inoculated mice.
Yamanaka A; Pitaksajjakul P; Ramasoota P; Konishi E
Vaccine; 2015 Nov; 33(45):6070-7. PubMed ID: 26259543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
